SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Suchard Marc)
 

Sökning: WFRF:(Suchard Marc) > Thirty-Day Outcomes...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006856naa a2201333 4500
001oai:gup.ub.gu.se/311140
003SwePub
008240528s2021 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/3111402 URI
0247 a https://doi.org/10.1542/peds.2020-0429292 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Duarte-Salles, Talita4 aut
2451 0a Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.
264 c 2021-09-01
264 1b American Academy of Pediatrics (AAP),c 2021
520 a To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children and adolescents diagnosed or hospitalized with coronavirus disease 2019 (COVID-19) and to compare them in secondary analyses with patients diagnosed with previous seasonal influenza in 2017-2018.International network cohort using real-world data from European primary care records (France, Germany, and Spain), South Korean claims and US claims, and hospital databases. We included children and adolescents diagnosed and/or hospitalized with COVID-19 at age <18 between January and June 2020. We described baseline demographics, comorbidities, symptoms, 30-day in-hospital treatments, and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome, multisystem inflammatory syndrome in children, and death.A total of 242158 children and adolescents diagnosed and 9769 hospitalized with COVID-19 and 2084180 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were more common among those hospitalized with versus diagnosed with COVID-19. Dyspnea, bronchiolitis, anosmia, and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital prevalent treatments for COVID-19 included repurposed medications (<10%) and adjunctive therapies: systemic corticosteroids (6.8%-7.6%), famotidine (9.0%-28.1%), and antithrombotics such as aspirin (2.0%-21.4%), heparin (2.2%-18.1%), and enoxaparin (2.8%-14.8%). Hospitalization was observed in 0.3% to 1.3% of the cohort diagnosed with COVID-19, with undetectable (n < 5 per database) 30-day fatality. Thirty-day outcomes including pneumonia and hypoxemia were more frequent in COVID-19 than influenza.Despite negligible fatality, complications including hospitalization, hypoxemia, and pneumonia were more frequent in children and adolescents with COVID-19 than with influenza. Dyspnea, anosmia, and gastrointestinal symptoms could help differentiate diagnoses. A wide range of medications was used for the inpatient management of pediatric COVID-19.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a Adolescent
653 a Age Distribution
653 a COVID-19
653 a complications
653 a diagnosis
653 a drug therapy
653 a epidemiology
653 a Child
653 a Child
653 a Preschool
653 a Cohort Studies
653 a Comorbidity
653 a Databases
653 a Factual
653 a Diagnosis
653 a Differential
653 a Female
653 a France
653 a epidemiology
653 a Germany
653 a epidemiology
653 a Hospitalization
653 a statistics & numerical data
653 a Humans
653 a Infant
653 a Infant
653 a Newborn
653 a Influenza
653 a Human
653 a complications
653 a diagnosis
653 a epidemiology
653 a Male
653 a Republic of Korea
653 a epidemiology
653 a Spain
653 a epidemiology
653 a Symptom Assessment
653 a Time Factors
653 a Treatment Outcome
653 a United States
653 a epidemiology
7001 a Vizcaya, David4 aut
7001 a Pistillo, Andrea4 aut
7001 a Casajust, Paula4 aut
7001 a Sena, Anthony G4 aut
7001 a Lai, Lana Yin Hui4 aut
7001 a Prats-Uribe, Albert4 aut
7001 a Ahmed, Waheed-Ul-Rahman4 aut
7001 a Alshammari, Thamir M4 aut
7001 a Alghoul, Heba4 aut
7001 a Alser, Osaid4 aut
7001 a Burn, Edward4 aut
7001 a You, Seng Chan4 aut
7001 a Areia, Carlos4 aut
7001 a Blacketer, Clair4 aut
7001 a DuVall, Scott4 aut
7001 a Falconer, Thomas4 aut
7001 a Fernandez-Bertolin, Sergio4 aut
7001 a Fortin, Stephen4 aut
7001 a Golozar, Asieh4 aut
7001 a Gong, Mengchun4 aut
7001 a Tan, Eng Hooi4 aut
7001 a Huser, Vojtech4 aut
7001 a Iveli, Pablo4 aut
7001 a Morales, Daniel R4 aut
7001 a Nyberg, Fredrik,d 1961u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine4 aut0 (Swepub:gu)xnybef
7001 a Posada, Jose D4 aut
7001 a Recalde, Martina4 aut
7001 a Roel, Elena4 aut
7001 a Schilling, Lisa M4 aut
7001 a Shah, Nigam H4 aut
7001 a Shah, Karishma4 aut
7001 a Suchard, Marc A4 aut
7001 a Zhang, Lin4 aut
7001 a Zhang, Ying4 aut
7001 a Williams, Andrew E4 aut
7001 a Reich, Christian G4 aut
7001 a Hripcsak, George4 aut
7001 a Rijnbeek, Peter4 aut
7001 a Ryan, Patrick4 aut
7001 a Kostka, Kristin4 aut
7001 a Prieto-Alhambra, Daniel4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa4 org
7730 t Pediatricsd : American Academy of Pediatrics (AAP)g 148:3q 148:3x 1098-4275x 0031-4005
8564 u https://publications.aap.org/pediatrics/article-pdf/148/3/e2020042929/1227638/peds_2020042929.pdf
8564 8u https://gup.ub.gu.se/publication/311140
8564 8u https://doi.org/10.1542/peds.2020-042929

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy